Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ClearPoint Neuro, Inc. (CLPT : NSDQ)

• Company Description    ClearPoint Neuro Inc. provides neurosurgery platform which includes hardware, software, clinical case and market development services for gene therapy cases principally in the United States and Europe. ClearPoint Neuro Inc., formerly known as MRI Interventions Inc., is based in Irvine, California. Number of Employees: 80

• Price / Volume Information    Yesterday's Closing Price: $9.35 Daily Weekly Monthly 20 Day Moving Average: 235,624 shares Shares Outstanding: 23.71 (millions) Market Capitalization: $221.67 (millions) Beta: 1.26 52 Week High: $22.80 52 Week Low: $7.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.21% -3.10% 12 Week 18.50% 24.76% Year To Date -16.67% -2.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 120 S. SIERRA AVE. SUITE 100 - SOLANA BEACH,CA 92075 USA ph: 888-287-9109 fax: 949-900-6834 hhurwitz@clearpointneuro.com http://www.clearpointneuro.com

• General Corporate Information    Officers Joseph M. Burnett - Chief Executive Officer and President R. John Fletcher - Chairman Danilo D'Alessandro - Chief Financial Officer Lynnette C. Fallon - Director Pascal E.R. Girin - Director Peer Information ClearPoint Neuro, Inc. (ABMD) ClearPoint Neuro, Inc. (DMDS) ClearPoint Neuro, Inc. (CPWY.) ClearPoint Neuro, Inc. (EQUR) ClearPoint Neuro, Inc. (ECIA) ClearPoint Neuro, Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 18507C103 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 23.71 Most Recent Split Date: 7.00 (0.03:1) Beta: 1.26 Market Capitalization: $221.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.85 Price/Cash Flow: - Price / Sales: 12.81 EPS Growth vs. Year Ago Period: -30.77% vs. Previous Quarter: 10.53% Sales Growth vs. Year Ago Period: 24.84% vs. Previous Quarter: 17.49% ROE 03/31/22 - -33.94 12/31/21 - -31.18 09/30/21 - -34.22 ROA 03/31/22 - -23.59 12/31/21 - -20.52 09/30/21 - -19.35 Current Ratio 03/31/22 - 14.60 12/31/21 - 13.02 09/30/21 - 14.17 Quick Ratio 03/31/22 - 13.16 12/31/21 - 11.98 09/30/21 - 13.31 Operating Margin 03/31/22 - -91.51 12/31/21 - -88.41 09/30/21 - -75.28 Net Margin 03/31/22 - -91.51 12/31/21 - -88.41 09/30/21 - -75.28 Pre-Tax Margin 03/31/22 - -91.51 12/31/21 - -88.41 09/30/21 - -75.28 Book Value 03/31/22 - 1.93 12/31/21 - 2.06 09/30/21 - 1.97 Inventory Turnover 03/31/22 - 1.18 12/31/21 - 1.27 09/30/21 - 1.45 Debt-to-Equity 03/31/22 - 0.22 12/31/21 - 0.20 09/30/21 - 0.40 Debt-to-Capital 03/31/22 - 17.72 12/31/21 - 16.78 09/30/21 - 28.53

Powered by Zacks Investment Research ©